Inhibition of vascularization in tumor growth.

The transition to a vascular phase is a prerequisite for fast tumor growth. During the avascular phase, the neoplasm feeds only from the (relatively few) existing nearby blood vessels. During angiogenesis, the number of capillaries surrounding and infiltrating the tumor increases dramatically. A model which includes physical and biological mechanisms of the interactions between the tumor and vascular growth describes the avascular-vascular transition. Numerical results agree with clinical observations and predict the influence of therapies aiming to inhibit the transition.

[1]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[2]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[3]  C. A. Condat,et al.  Competition effects in the dynamics of tumor cords. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.

[4]  N. Ferrara,et al.  Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. , 1998, The American journal of pathology.

[5]  H. Suzuki,et al.  An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. , 1998, Hybridoma.

[6]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[7]  S Torquato,et al.  Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. , 2000, Journal of theoretical biology.

[8]  José C. M. Mombach,et al.  Single cell motion in aggregates of embryonic cells. , 1996, Physical review letters.

[9]  H. Wu,et al.  Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Harris,et al.  Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.

[11]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[12]  M Scalerandi,et al.  Emergence of taxis and synergy in angiogenesis. , 2001, Physical review letters.

[13]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[14]  Philip K. Maini,et al.  Cellular pattern formation during Dictyostelium aggregation , 1995 .

[15]  R. Kerbel.  A cancer therapy resistant to resistance , 1997, Nature.

[16]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[17]  J. Sherratt,et al.  A two parameter family of travelling waves with a singular barrier arising from the modelling of extracellular matrix mediated cellular invasion , 1999 .

[18]  M Magnano,et al.  Effects of anatomical constraints on tumor growth. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.

[19]  M. Toi,et al.  Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. , 2001, The Lancet. Oncology.

[20]  R. Weichselbaum,et al.  Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.

[21]  Helen M. Byrne,et al.  A weakly nonlinear analysis of a model of avascular solid tumour growth , 1999, Journal of mathematical biology.

[22]  A Romano,et al.  Analysis of a "phase transition" from tumor growth to latency. , 2000, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.

[23]  Pier Paolo Delsanto,et al.  Nutrient competition as a determinant for cancer growth , 1999 .

[24]  M. Gondo,et al.  Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene , 1999, Nature Biotechnology.

[25]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[26]  N. Britton,et al.  Stochastic simulation of benign avascular tumour growth using the Potts model , 1999 .

[27]  J. M. Pastor,et al.  Super-rough dynamics on tumor growth , 1998 .

[28]  M. J. Holmes,et al.  A mathematical model of tumour angiogenesis incorporating cellular traction and viscoelastic effects. , 2000, Journal of theoretical biology.

[29]  M Scalerandi,et al.  Diffusion with evolving sources and competing sinks: development of angiogenesis. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.

[30]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[31]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[32]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.